Diagnostic technique for malignant process in human body

FIELD: medicine.

SUBSTANCE: invention refers to medicine, namely to diagnosing malignant processes in a human body. A diagnostic technique for a malignant process in a human body consisting in sampling a patient's living tissue, grinding, mixing with physiologic saline to a state of suspension, keeping and agitating under certain conditions, then centrifuging, separating supernatant and detecting cancer-specific markers by an immunochemiluminisent assay.

EFFECT: method exhibits a simple and high degree of malignant process detection in the human body, both at the early, and following stages of disease.

1 tbl


The invention relates to medicine, namely to the diagnosis of malignant processes in the human body. Cancer is one of the most frequent causes of death, often at a young age. Successful treatment is possible only in the early stages, which requires early detection. Determination of tumor markers makes it possible to successfully prevent and treat this severe pathology. The tumor markers are specific substances that are formed as a result of life of cancer (and sometimes normal) cells and are usually found in the blood and/or urine in cancer patients. They are extremely diverse in their structure, although in most cases are proteins or their derivatives. Some of them have high specificity, i.e., characteristic of one type of tumor, but can be found in other forms of cancer. Purposeful search specific and cheap nowadays. New tumor markers became an official numbered names, such as CA 19-9 for rectal cancer and pancreatic cancer, CA 15-3 for breast cancer and CA 125 for ovarian cancer. Many other open markers for the diagnosis of these types of cancer have not received further study because they did not show its advantages over the above But, unfortunately, even the specificity and sensitivity of recognized tumor markers leaves much to be desired. First, almost every person can be detected in the blood of a small number of tumor markers, which complicates the diagnosis at an early stage of tumor development. A significant increase in the level of tumor marker is often observed in the later stages, when the tumor is already quite advanced. Secondly, even when a relatively high level of tumor markers in the blood, many of them are non-specific: CEA, originally opened as a marker of colon cancer may be increased in patients with lung cancer and mammary glands, and the high level of CA 125 common in women with gynecological diseases non-neoplastic nature. Despite the fact that the tumor markers were developed for early (even at asymptomatic stage) cancer diagnosis, in practice, only prostate-specific antigen (PSA) to meet its purpose. In all other cases, accurate diagnosis of cancer is established only on the results of study under the microscope biopsy (sample of tissue) tumor. The main use of tumor markers in clinical diagnosis - monitoring of the disease and the effectiveness of the treatment, obtaining prognostic information. One of the tasks solved by the use of tumor markers is in the opportunity, in combination with other diagnostic methods, early differential diagnosis of tumors and monitoring the effectiveness of treatment. The dynamics of increasing levels of tumor markers usually allows to make a conclusion about the presence and nature of disease and metastasis and is of more interest than a single level, taken by itself. With regular monitoring of markers informative for tumor-specific localization, it is possible to detect metastasis in 4-6 months before clinical detection. During treatment or after surgery no decrease in the concentration of tumor markers indicates the inefficiency of the selected method of treatment. Unfortunately, still not characterized by any one tumor marker, with 100% specificity with respect to any authority.

Closest to the claimed method is the morphological diagnosis of malignant processes, which consists in extracting the tissue sample of the patient, maintaining the fabric in a fixed condition with the help of clamps, dehydration and further fill with paraffin. After pouring the wax and hardening of the sample make the drug by using a microtome. Then the sections from paraffin sample is placed on a glass slide, remove the paraffin, produce staining and cover top is glass. The mixture is placed under a microscope to determine the ultrastructure of cells and their components and diagnosis of malignant processes (Eliseev VG and others 1972).

The disadvantage of this method is the complexity of the process of preparing a diagnostic agent as well as a greater likelihood of obtaining a false result because when the diagnosis is investigated not the whole amount of tissue extracted from the body of the patient, and only the sections that difficult diagnosis in the early stages of tumor development.

Closest to the claimed device is diagnostic of malignant processes, which includes serially connected unit fixation, dehydration unit, thermostat, microtome, block staining, microscope (Eliseev VG and others 1972).

A disadvantage of the known device is the complexity of the process of preparing a diagnostic agent as well as manual labor on some stages, which reduces the quality of the final product and the reliability of the diagnosis of malignant processes in the human body.

The technical result is achieved in the present method of diagnosing malignant process is the simplicity and high degree of probability of detection of malignant processes in the human body as in the early stages of the disease, and n is the later. This is due to the fact that the level of a tumor marker can indicate the presence of abnormalities not only in the area from which the sample was collected tissue, but also about the extent of the distribution of ecoprocess.

The technical result is achieved in that in the method for the diagnosis of malignant process in the human body take the living tissue of the patient, crushed, mixed with 2 ml of physiological solution to a state of suspension, and then incubated for 5 minutes at a temperature of 20°C, then mix and again incubated for 5 minutes at 20°C, and the stages of incubation and mixing the suspension was repeated 3 times, then centrifuged at 10,000 rpm for 2 min, take the supernatant and immunochemiluminescence method determines the tumor markers.

The method is implemented as follows.

A tissue sample of the patient is placed in a test tube and crushed with a sterile tip or special pestle. To the minced tissue add 2 ml of physiological solution and stirred on the vortex to obtain a suspension. Then the test tube is placed in a thermostat at 20°C for 5 minutes. Remove the tube from the refrigerator, mix on a vortex and again placed in thermostat. Procedures cooling, stirring and cooling was repeated 3 times. Then the tube with the tissue in physiological solution centrifuger the t at 10,000 rpm for 2 minutes. In a clean test tube select the supernatant, which carried out the determination of the marker using standard immunochemiluminescence method. The table shows the levels of the tumor marker in diagnosis by blood and by the present method.

The level of the marker in the blood and in the tumor tissue in cancer patients depending on the stage of the disease
Patient No. East./diseaseThe diagnosis of the diseaseThe level of the marker in the bloodThe level of the marker in the tumor tissue
B-Naya A. No. 23Breast cancer T1NoMoSA-3: 0.10 u/mlSA-3: 73.82 u/ml
B-Naya R. No. 43Breast cancer T1N1MoSA-3: 6.10 u/mlSA-3: 123.8 u/ml
B-Naya K. No. 48Breast cancer T3N2M1SA-3: 46.1 u/mlSA-3: >200 u/ml
B-Noia. No. 13Stomach cancer T1NoMoREA: 0.74 ng/ml REA: 35.7 ng/ml
B-Neue. No. 63Stomach cancer T2N1MoREA: 3.74 ng/mlREA: 43.74 ng/ml
B-Naya K. No. 73Stomach cancer T3N1M1REA: 23.74 ng/mlREA: 146.74 ng/ml
B-Naya K. No. 48Cancer of the uterus T3N1M1REA: 23.74 ng/mlREA: 223.84 ng/ml
B-Naya K. No. 48Ovarian cancer T1NoMoSA: 2.0 u/mlCA 125: 56.10 u/ml
B-Naya K. No. 48Ovarian cancer T3N2M1CA 125: 196.10 u/mlCA 125: >200 u/ml

The normal concentration in the blood serum: SA-3 and SA - less than 30 u/ml; REA - 10 ng/ml.

The table shows that diagnosis of the disease at the level of the tumor marker in the blood has a very low rate of detection of diseases (actually at the stage of having the appearance of metastases).

The inventive method allows to detect the disease at earlier stages, when treatment is more effective and depending on the level of the marker to correct stage of illness the project.

The inventive method for the diagnosis of malignant process in the human body is a high-tech, simple diagnostic test that allows a high degree of accuracy to detect malignancies in humans, both early and later stages of the disease and correct treatment.

A method for diagnosing a malignant process in the human body, which consists in the fact that I'm living tissue of the patient, crushed, stirred in 2 ml of physiological solution to a state of suspension, and then incubated 5 min at 20°C, then mix and again incubated 5 min at 20°C, and the stages of incubation and mixing was repeated 3 times, then centrifuged at 10,000 rpm for 2 min, take the supernatant and immunochemiluminescence method for the determination of the marker.


Same patents:

FIELD: medicine.

SUBSTANCE: separated films are placed for 6 hours into 30% water solution of alcohol in amount, equal to preparation volume. After that, they are washed in flowing water for 10 minutes in order to remove let down mesothelial cells, fixed in formalin, washed and placed into 96% alcohol for 30 minutes to degrease the surface, after that, sensitised in 10% solution of silver nitrate for 10 minutes. Then silver is impregnated by keeping preparation for 30 minutes in ammonium solution of silver nitrate, washed for 2 minutes in 5 parts of distilled water to remove impregnated silver from basal membrane, remaining impregnated silver is reduced into metal state with 1% formalin during 30 seconds to give preparation blackish colour. Microscopy is carried out on unfolded wet free film preparations by means of microscopes with flat field of incident light, provided with objectives for work without cover glasses, at unilateral oblique incident illumination, carrying out for said purpose edge blocking half of light flow of standard-issue episystem of microscope illumination in mode of dark field with non-transparent shutter.

EFFECT: method improvement.

3 cl, 11 dwg

FIELD: medicine.

SUBSTANCE: motion parameters of ciliated epithelium cilia are measured. The value Vc=9.6-11.3 mm/min corresponds to a normal functioning of mucociliary transport (MCT). Chronic rhinosinusitis requires a complex conventional therapy that involves administering mucoactive preparations. The therapy is continued with such mucoactive preparation that caused the highest speed of the cilia.

EFFECT: method allows individual prescription to a patient of the mucoactive preparation and provides higher local clinical effectiveness.

2 cl, 2 ex

FIELD: medicine.

SUBSTANCE: fertile window is determined in the menstrual cycle by saliva electrolyte composition test ensured by electrolytic current generated by potassium ion diffusion in the saliva. That is ensured by the pre-evaluation of electrolytic current in the absence of the fertile window, thereafter this value is used as a reference to be matched with the relevant present electrolytic current when determining fertile window time and length. The fertile window time is determined by increasing electrolytic current as compared with the same value in the absence of the fertile window, and the fertile window length is described by the increasing time of the corresponding electrolytic current.

EFFECT: higher accuracy of determination of the fertile window time and length.

3 dwg, 3 ex

FIELD: medicine.

SUBSTANCE: invention contains body which consists of base and cover, made from fluoroplast, and device for imitation of optical properties of various types of live biological tissues. Device includes set of layer-by-layer placed elements which possess light-dispersing, fluorescent and light-absorbing optical properties. Layer-by-layer placed elements represent polymer optical films, whose spectral linear coefficients of absorption and dispersion correspond to spectral linear coefficients of light absorption by biological tissues with superficial and epidermal melanin, blood saturated with oxygen on 5-100%, spectral linear coefficient of light dispersion by collagen fibres and dense tissue structure without blood. Wavelengths of fluorescence of polymer optic films correspond to wavelengths of fluorescence of respiratory cell enzymes of biological tissue.

EFFECT: application of invention extends functional possibilities of device and ensures calibration and check-up of vast range of devices and apparatuses of non-invasive medical spectrophotometry.

3 cl, 1 dwg, 1 tbl

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to ophthalmology, and can be applied in diagnostics of primary open-angle glaucoma by infrared spectrometry of lachrymal fluid. Ifrared spectrometry method is used for examination of lachrymal fluid, where infrared transmittance per 1 second is determined in nine sub-bands of electromagnetic radiation spectre: 3500-3200 cm-1, 3085-2832 cm-1, 2120-1800 cm-1, 1710-1610 cm-1, 1600-1535 cm-1, 1542-1425 cm-1, 1430-1210 cm-1, 1127-1057 cm-1, 1067-930 cm-1. Integral system indicator of Mahalanobis criterion is calculated by spectral characteristic data obtained in these bands, and with the indicator equal to 34 conventional units or more, primary open-angle glaucoma is diagnosed.

EFFECT: fast and reliable diagnostics of primary open-angle glaucoma.

2 ex

FIELD: medicine.

SUBSTANCE: living cells of wound prints are put in dissolved drugs adjusted and exposed to microelectrophoresis in a sign-variable field. The observed maxima of epithelial and red blood cells amplitudes in the dissolved drug adjusted enables to consider the drug of this type as the most proper in wound repair.

EFFECT: application of the invention allows for the more objective analysis of the wound condition and the efficient adjustment of the drugs for wound regeneration taking into account specific features of the patient.

2 ex

FIELD: medicine.

SUBSTANCE: method relates to experimental and clinical pharmacology. Analysed substance is applied in layers on choriallantoic membrane of 10-day chick embryo and injury of membrane vessels is evaluated. Evaluation of change of blood flow rate and heart rate is carried out in dynamics by means of ultrasonic Dopplerography. Ultrasound sensor is first placed on the surface of choriallantoic membrane at angle to examined venous vessel, and after that is submerged into albumen to located on yolk sac arteries, at angle to them, and venous and arterial Dopplerograms are obtained respectively. Control measurement is performed before applying layer of analysed substance. By obtained Dopplerograms linear rate of blood flow Vs and heart rate are determined and hypo- or hypertensive impact of substance is evaluated by their change.

EFFECT: invention allows to increase accuracy and objectivity of investigation results interpretation for wide range of medications, increase economy and quickness of obtaining results.

18 tbl, 8 ex

FIELD: physics.

SUBSTANCE: device has an optical reception system, an illuminator, a sample positioning unit, which includes a reflecting element and a transparent carrier, placed one in front of the other along an optical axis. The working surface of the carrier is situated in the illumination zone of the first illuminator. The device has a second illuminator. The sample positioning unit is such that, a second transparent carrier can be installed under the surface of the first carrier along the optical axis. The working surface of the carrier is situated in a zone illuminated by the first and second illuminators. The illuminators have a light-absorbing layer for absorbing light reflected from the surface of the sample carrier and from the surface of the reflecting element.

EFFECT: use of the invention allows for illumination of the entire working area without reducing the signal to noise ratio.

13 cl, 10 dwg, 1 ex, 1 tbl

FIELD: medicine.

SUBSTANCE: invention can be used for tumor visualisation using hyperpolarisable 13C-pyruvate as magnetic resonance imaging agent, which can distinguish healthy tissue from tumor tissue. The following shall be performed: a) acquisition of direct 13C-MP images of 13C-pyruvate and its 13C-containing metabolites of alanine and lactate in the patient previously injected with composition containing hyperpolarisable 13C-pyruvate, b) correcting lactate signal with respect to quantity of pyruvate and/or alanine with acquisition of lactate relative to pyruvate and/or lactate relative to alanine image whereby tumor tissue is indicated by the highest signal and/or high weighted lactate signal relative to pyruvate signal and/or lactate signal relative to alanine signal in specified13C-images.

EFFECT: improved imaging accuracy when distinguishing healthy tissue from tumor tissue.

8 cl, 2 dwg, 5 ex

FIELD: medicine.

SUBSTANCE: invention refers to biological and medical examinations, particularly to methods of organism biosubstrata, mainly human or animal, analysis for iodine content and can be used in examination of iodine metabolism in said organisms. The method involves biosubstratum sampling, binding and preparing for analysis for iodine content. The sample is bound by freezing at temperature -18…-20°C, before the analysis the samples of thickness not exceeding 1 mm are dried at temperature 100°C within 30…45 minutes. Then platinum layer of thickness up to 1 mcm is sprayed on the sample surface by ion evaporation. The analysis involves X-ray microspectral method with using a wavelength dispersion wherein the sample is exposed to primary electron beam directed thereon to evaluate number of frames of characteristic X-ray radiation. In the similar way, number of frames of characteristic X-ray radiation in a standard sample with known iodine content. Actual iodine content in organism biosubstrata is determined by comparing number of frames in biosubstratum and standard samples.

EFFECT: development of effective method of organism biosubstrata analysis for iodine content.

1 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to orthopedics. In order to estimate state of bone tissue in case of immobilisation osteoporosis in a laboratory animal examined are homogenates: bone, muscular, bone marrow of any extremity and peripheral blood. Biochemical and integral parametres are determined. Five factor variables F1-F5 are calculated using values of biochemical and integral parametres, constant values of factor coefficients of biochemical parametres and free coefficients. After that calculated is the value of discriminant function, whose value is used to estimate bone state as normal or conclusion about presence of immobilisation osteoporosis is made.

EFFECT: method increases accuracy and efficiency, has high stability of immobilisation osteoporosis recognition.

1 ex, 3 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to dentistry. In order to determine bleeding sickness type clinical manifestations are determined and assigned point marks, by table 2, contained in the description. Obtained points are summed up, and is the sum of points equals 3 and more index Z is calculated by formula: Z=Σ10R, where R is index of the degree, to which it is necessary to raise figure 10 in case if clinical manifestations, given in table 3, contained in the description, are present. If index Z is within the range 10-30, made is conclusion about high probability of inherent haemorrhagic disease with microcirculation type of bleeding sickness; from 50 to 499 - of acquired haemorrhagic disease with microcirculation type of bleeding sickness; from 500 to 3000 - of inherent haemorrhagic disease with mixed type of bleeding sickness; from 10000 to 50000 - of inherent haemorrhagic disease with hematoma type of bleeding sickness; from 100000 to 500000 - of acquired hemophilia; and if Z value is higher than 1000000 - simulation of haemorrhagic disease.

EFFECT: method increases efficiency of detection of patients who may develop bleeding after tooth extraction.

4 dwg, 1 ex, 5 tbl

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, namely to methods of predicting post-operational complications, namely to methods of predicting development of scars after previous acne. In order to predict scar development content of receptor antagonist of interleukin-1 (RAIL) is determined during 15 days after resolution of inflammatory process. Scarless development of process is diagnosed at level RAIL in peripheral blood serum after disease being within physiological norm (300-800 pg/ml). If level of RAIL is lower than said norm prediction of acne complication in form of skin scars is diagnosed. Possibility of development of hypertrophic scars is predicted if RAIL concentration is lower than 200 pg/ml.

EFFECT: method makes it possible to predict type of complications after previous acne, therefore correcting therapy carried out in due time can prevent risk of skin scar formation and improve patient's life quality.

2 cl, 1 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular, to neurosurgery. Minimal diametre of trepanation is calculated by formula: where: D1 is diametre in case if unilateral trepanation is performed; D2 is diametre in case of bilateral trepanation; W is mass-effect of trauma (%), which is calculated for patients with presence or absence of additional intracranial formation: hematoma, hydroma, hygroma, contusion focus, by given mathematical formulae. During calculation of mass-effect taken into account are: volume of additional formation, in cubic cm, and estimation of patient's state by GLASGO scale.

EFFECT: method makes it possible to determine optimal dimensions of trepanation hole for carrying out operations of decompression orientation in treatment of craniocerebral trauma in children.

2 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to infectious disease, and can be used for prediction of antiretroviral therapy efficiency in case of HIV-infection. For this purpose by method of solid-phase immunoenzyme assay level of cytokines is determined. If indices of soluble tumour necrosis factor alpha receptor protein 75 are from 4335.48 to 6001.86 pg/ml, soluble tumour necrosis factor alpha receptor protein 55 - from 768.72 to 1323.87 pg/ml and soluble interleukin-6 receptor from 1770.77 to 3800.31 pg/ml, favourable clinic course of HIV-infection after 1-3 months since beginning of antiretroviral therapy is predicted.

EFFECT: method ensures increase of accuracy of antiretroviral therapy efficiency prediction due to selection of certain immunological criteria.

1 dwg, 7 tbl, 3 ex

FIELD: medicine.

SUBSTANCE: invention relates to field of medicine, in particular to nephrology. In order to predict progressing of steroid-resistant nephrotic syndrome in case of glomerulonephritis in children clinical-morphologic predictors of progressing and efficiency of the 1-st course of immunosuppressive therapy are estimated. As clinical-morphologic predictors of progressing determined are: "focal-segmental glomerulosclerosis, angiopathy of retinal vessels, increase of creatinine in blood in disease manifestation, stable increase of cholesterol level in blood >6.7 mmol/l, stable increase of fibrinogen in blood >4 g/l, disturbance of day rhythm of arterial pressure by "night-peackers" and "non-dippers" type, left ventricle hypertrophy in echocardiographic examination, increased size of kidneys in ultrasonic examination". If more than four clinical-morphologic predictors are detected and/or there is no effect from the 1-st course of immunosuppressive therapy, progressing of steroid-resistant nephrotic syndrome in case of glomerulonephritis in children is predicted.

EFFECT: method makes it possible to predict progressing course of steroid-resistant nephrotic syndrome in case of glomerulonephritis in children on the basis of early detection of clinical and morphologic predictors.

2 ex, 4 tbl

FIELD: medicine.

SUBSTANCE: invention relates to medicine, namely to neurology, and can be used for prediction of complications, associated with endured first acute cerebral circulation disorder. At 3-4 week of acute cerebral circulation disorder state of cognitive status in patient is determined by means of MMSE test, degree of neurologic deficiency is determined using Scandinavian stroke scale NIHSS, education level is determined. Degree of cognitive disorder in early rehabilitation period of stroke (K) is calculated by formula: K=18.83+0.71·X+0.33·Y-0.27·Z; where X is patient's education level, where 1 point is incomplete high education, 2 points - high education, 3 points - specialised high education, 4 points - higher education, Y is result of MMSE test in acute period - in points, Z is value of NIHSS stroke scale at the end of acute period - in points. If K value is 28-30 points - no disorders of cognitive function will take place, 24-27 points - pre-dement cognitive disorders will take place - 1 degree, 20-23 points - dementia of light expression degree - 2 degree, 11-19 points - dementia of moderate expression degree - 3 degree will take place.

EFFECT: providing early prediction of cognitive deficiency formation in patients, who endured acute cerebral circulation disorder for the first time, namely ischemic stroke of hemispheric localisation, aimed at administration of preventive treatment in due time.

5 ex

FIELD: medicine.

SUBSTANCE: invention relates to medicine, in particular to ophthalmology. Acute blood serum and lachrymal fluid of a patient with uveitis are analysed for prostaglandin E2 concentration with calculating a ratio of blood serum prostaglandin E2 concentration to lachrymal fluid E2 prostaglandin E2 concentration. The value within 0.54-2.93 makes to diagnose rheumatoid arthritis, while the value 8.3-26.0 shows Marie-Strumpell disease.

EFFECT: method provides more frequent diagnosis of rheumatic uveites.

4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, and can be used for determining a severity level of acute pancreatitis. That is ensured by patient's lymphocyte chemoluminescence and measuring a production level of active forms of oxygen. Spontaneous chemoluminescence Imax within 46.12 to 266.12, Squar within 2.5E+05 to 7.8E+04, Tmax within 3.2 to 4.5, Tcent within 9.2 to 17.4, Simtr within 2.6E-01 to 5. OE-01 and activated chemoluminescence Imax within 48.0 to 151.0, Squar within 1.2E+05 to 3.9E+05, Tmax within 4.3 to 8.4, Tcent within 27.7 to 30.3, Simtr within 1.7E-01 to 2.8E-01 show a mild severity of acute pancreatitis. Herein, Imax is chemoluminescence intensity, Squar is a curve area, Tmax is peaking time, Tcent is percent peaking time, Simtr is curve symmetry, E is estimated chemoluminescence activity described by kinetic parametres of the chemoluminescence reaction curves. In case of Imax> 266.2, Squar≤2.4E+05, Tmax> 4.6, Tcent≤9.1, Simtr> 5.1E-01 and activated Imax> 151.1, Squar> 4.0E+05, Tmax> 8.5, Tcent> 30.4, Simtr> 2.9E-01, the severity level is considered to be moderate. Spontaneous Imax≤46.0, Squar> 7.9E+04, Tmax≤3.1, Tcent> 17.5, Simtr≤2.5E-01 and activated Imax≤47.9, Squar≤1.1E+05, Tmax≤4.2, Tcent≤27.6, Simtr≤1.6E-01 indicate the severe disease.

EFFECT: method allows higher objectivity and fast determination of the severity of a pathological process and prescription of enhanced antibacterial and detoxification therapy in cases of the severe disease.

2 tbl, 4 ex

FIELD: medicine.

SUBSTANCE: invention refers to medicine, particularly to therapy, pediatrics, threpsology. It involves clinical and laboratory examination, a subject is finger skin. Nail bones of three fingers are coated simultaneously with 7.5 % aqueous hydrogen peroxide on a palmar surface. A physiologically optimum availability is indicated by no skin albication; lower normal level decrease of availability presents single albication points; selenium deficiency is shown by merged albication regions taking a greater portion of the coated surface.

EFFECT: method allows screening examination of population.

1 tbl, 3 ex

FIELD: medicine, clinical toxicology.

SUBSTANCE: at patient's hospitalization one should gather the data of clinical and laboratory values: on the type of chemical substance, patient's age, data of clinical survey and laboratory values: body temperature, the presence or absence of dysphonia, oliguria being below 30 ml/h, hemoglobinuria, erythrocytic hemolysis, exotoxic shock, glucose level in blood, fibrinogen and creatinine concentration in blood serum, general bilirubin, prothrombin index (PTI), Ph-plasma, the state of blood clotting system. The state of every sign should be evaluated in points to be then summed up and at exceeding the sum of points being above "+20" one should predict unfavorable result. At the sum of "-13" prediction should be stated upon as favorable and at "-13" up to "+20" - prediction is considered to be doubtful.

EFFECT: higher accuracy of prediction.

2 ex, 3 tbl